Treatment of Non-monosymptomatic Nocturnal EnuresisPhase 3NCT07398261
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
A Phase 3 study testing Mirabegron 25 MG in people with Treatment of Non-monosymptomatic Nocturnal Enuresis, run by Menoufia University at 1 site in Egypt.
Trial summary
This phase 3 clinical trial will compare use of individual treatment with mirabegron or desmopressin and their combination for treatment of non-monosymptomatic nocturnal enuresis in children Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Treatment of Non-monosymptomatic Nocturnal Enuresis
- What is being tested?
- Mirabegron 25 MG
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 151 participants
- Where
- 1 siteEgypt
- Study dates
- 28 Nov 2023to 1 Nov 2026
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Non-monosymptomatic nocturnal enuresis
Who cannot join
- monosymptomatic nocturnal enuresis
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Menoufia faculty of medicine
Shibīn al Kawm, Monufia Governorate, 32616
About this study
This phase 3 clinical trial will compare use of individual treatment with mirabegron or desmopressin and their combination for treatment of non-monosymptomatic nocturnal enuresis in children
- Being tested
- Mirabegron 25 MG
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mirabegron 25 MGDrug
Also called vibegron
Evaluate the efficacy of individual mirabegron or in combination for treatment of non-monosymptomatic nocturnal enuresis in children
| Study group | Role | What they receive |
|---|---|---|
| Mirabegron 25 mg | Active comparator | Patients received mirabegron 25 mg orally Receives: Drug: Mirabegron 25 MG |
| no intervention | No intervention | no intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Partial or complete response
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start28 Nov 2023
- Primary completion1 Nov 2026 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Treatment of Non-monosymptomatic Nocturnal EnuresisStudies of the same condition, open and under way.
- More trials run by Menoufia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 151 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Menoufia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammed Ali abdelghaffar, Menoufia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07398261
- Sponsor's protocol ID
- Urol9/2023
- Status last verified
- Oct 2026
- First submitted
- 29 Aug 2023
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
- ClinicalTrials.gov ID
- NCT07398261
- Acronym / sponsor ID
- Urol9/2023
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 151 participants (estimated)
- Lead sponsor
- Menoufia UniversityUniversity, hospital or other
- Study start
- 28 Nov 2023 (actual)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase 3 clinical trial will compare use of individual treatment with mirabegron or desmopressin and their combination for treatment of non-monosymptomatic nocturnal enuresis in children
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mirabegron 25 mg | Active comparator | Drug: Mirabegron 25 MGPatients received mirabegron 25 mg orally |
| no intervention | No intervention | –no intervention |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Non-monosymptomatic nocturnal enuresis
Key exclusion criteria (1 listed)
- monosymptomatic nocturnal enuresis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mirabegron 25 MGAlso: vibegronEvaluate the efficacy of individual mirabegron or in combination for treatment of non-monosymptomatic nocturnal enuresis in children | Drug | Mirabegron 25 mg |
Primary outcome
Partial or complete response
Time frame: 18 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Mirabegron 25 MG in people with Treatment of Non-monosymptomatic Nocturnal Enuresis, run by Menoufia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Partial or complete response (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.